Cadonilimab Injection

DRUG5 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, Shenzhen People's Hospital, RemeGen Co., Ltd.

Conditions

Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic TherapyAdvanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic TherapyAdvanced Hepatocellular Carcinoma That Has Failed at Systemic TherapyGastric CancerGastroesophageal Junction AdenocarcinomaLocally Advanced Rectal Carcinoma

Phase 1

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours

Tianjin Medical University Cancer Institute and HospitalAdvanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy

Start: 2022-11-25End: 2025-11-25Target: 30Updated: 2022-12-09

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma

Active, not recruitingNCT05644379

Tianjin Medical University Cancer Institute and HospitalAdvanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy

Start: 2022-11-24End: 2026-11-01Target: 30Updated: 2026-02-09

Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Tianjin Medical University Cancer Institute and HospitalAdvanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Start: 2024-06-01End: 2025-05-01Target: 30Updated: 2024-04-15

Phase 2

Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer

CompletedNCT05792735

Shenzhen People's HospitalLocally Advanced Rectal Carcinoma

Start: 2023-04-11End: 2025-01-31Updated: 2025-02-05

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

RecruitingNCT06221748

RemeGen Co., Ltd.Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

Start: 2024-02-22End: 2027-12-31Target: 90Updated: 2024-04-03

Related Papers

Abstract 5236: Updated exploratory biomarker analysis of cadonilimab plus regorafenib as second-line or later therapy in advanced hepatocellular carcinoma: Identification of Bola3 as a potential predictive biomarker

Cancer Research2026-04-03

Abstract CT172: Updated efficacy and safety data for cadonilimab plus regorafenib as second-line or later therapy in advanced hepatocellular carcinoma (aHCC)

Cancer Research2025-04-25

Short-course radiation(SCRT) followed by 6 cycles of cadonilimab plus mFOLFOX6 as neoadjuvant therapy for patients with locally advanced rectal cancer (LARC): A multicenter, single arm, phase II trial (NeoCaCRT).

Journal of Clinical Oncology2025-01-271 citations

A study of cadonilimab combined with regorafenib as second-line or later therapy in patients with advanced hepatocellular carcinoma (aHCC).

Journal of Clinical Oncology2023-06-01